Sorry to hear about your diagnosis. As has already been said, the course of MS is extremely variable and it's almost impossible to predict the individual outcome of any given patient.
As DMF (i.e. tecfidera) has only been approved for a few years, it is likely that the number of class 1 and 2 who are under treatment is small, thereby somewhat complicating the evalutation process.
Unfortunately, at this stage, it will be very difficult to give you any clear advice on how your prospects of class 1 + OML recertification is going to pan out. Get your consultant to contact the appropriate CAA advisor asap, as this could be a more lengthy process.
Best of luck!